Healthcare provider profile · identity verified

Mark Andrew Doane, MD

Family Practice · TACOMA, WA · NPI 1902836935

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	428	120
Lisinopril	Lisinopril	274	86
Amlodipine Besylate	Amlodipine Besylate	229	72
Losartan Potassium	Losartan Potassium	225	72
Levothyroxine Sodium	Levothyroxine Sodium	195	49
Omeprazole	Omeprazole	163	50
Tamsulosin Hcl	Tamsulosin Hcl	159	48
Oxycodone Hcl	Oxycodone Hcl	155	30
Gabapentin	Gabapentin	149	44
Hydrochlorothiazide	Hydrochlorothiazide	146	49
Rosuvastatin Calcium	Rosuvastatin Calcium	145	48
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	129	35
Metformin Hcl	Metformin Hcl	129	41
Simvastatin	Simvastatin	127	34
Trazodone Hcl	Trazodone Hcl	118	34
Metoprolol Succinate	Metoprolol Succinate	109	35
Pantoprazole Sodium	Pantoprazole Sodium	94	32
Meloxicam	Meloxicam	90	33
Alvesco	Ciclesonide	82	22
Metoprolol Tartrate	Metoprolol Tartrate	81	23
Furosemide	Furosemide	77	21
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	70	19
Metformin Hcl Er	Metformin Hcl	67	16
Albuterol Sulfate Hfa	Albuterol Sulfate	64	32
Duloxetine Hcl	Duloxetine Hcl	63	20
Pregabalin	Pregabalin	63	11
Buspirone Hcl	Buspirone Hcl	62	12
Jardiance	Empagliflozin	60	17
Fluticasone Propionate	Fluticasone Propionate	56	18
Atenolol	Atenolol	54	16
Bupropion Hcl Sr	Bupropion Hcl	53	14
Allopurinol	Allopurinol	50	15
Famotidine	Famotidine	50	18
Mirtazapine	Mirtazapine	50	suppressed
Sertraline Hcl	Sertraline Hcl	49	13
Quetiapine Fumarate	Quetiapine Fumarate	48	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	44	16
Potassium Chloride	Potassium Chloride	40	14
Propranolol Hcl	Propranolol Hcl	40	12
Baclofen	Baclofen	39	suppressed
Finasteride	Finasteride	39	13
Ondansetron Odt	Ondansetron	37	12
Lorazepam	Lorazepam	36	suppressed
Terazosin Hcl	Terazosin Hcl	36	suppressed
Glipizide	Glipizide	35	12
Fluoxetine Hcl	Fluoxetine Hcl	34	11
Carvedilol	Carvedilol	33	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	32	17
Sumatriptan Succinate	Sumatriptan Succinate	31	suppressed
Tramadol Hcl	Tramadol Hcl	31	suppressed
Xarelto	Rivaroxaban	31	suppressed
Montelukast Sodium	Montelukast Sodium	30	suppressed
Morphine Sulfate Er	Morphine Sulfate	30	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	29	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	29	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	29	suppressed
Clopidogrel	Clopidogrel Bisulfate	27	11
Mupirocin	Mupirocin	27	12
Escitalopram Oxalate	Escitalopram Oxalate	25	suppressed
Hydralazine Hcl	Hydralazine Hcl	25	suppressed
Nystatin	Nystatin	25	suppressed
Creon	Lipase/Protease/Amylase	24	suppressed
Diclofenac Sodium	Diclofenac Sodium	24	suppressed
Fluconazole	Fluconazole	24	suppressed
Ozempic	Semaglutide	24	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	24	suppressed
Spironolactone	Spironolactone	23	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	22	14
Bupropion Xl	Bupropion Hcl	22	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	22	suppressed
Prednisone	Prednisone	22	suppressed
Tizanidine Hcl	Tizanidine Hcl	22	suppressed
Alprazolam	Alprazolam	21	suppressed
Humulin N	Insulin Nph Human Isophane	21	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	21	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	21	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	21	suppressed
Donepezil Hcl	Donepezil Hcl	20	suppressed
Ezetimibe	Ezetimibe	20	suppressed
Paroxetine Hcl	Paroxetine Hcl	20	suppressed
Methocarbamol	Methocarbamol	19	suppressed
Acyclovir	Acyclovir	18	suppressed
Ibuprofen	Ibuprofen	18	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	18	11
Morphine Sulfate	Morphine Sulfate	18	suppressed
Alendronate Sodium	Alendronate Sodium	17	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	17	suppressed
Ketoconazole	Ketoconazole	17	suppressed
Promethazine Hcl	Promethazine Hcl	17	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	17	suppressed
Estradiol	Estradiol	16	suppressed
Pravastatin Sodium	Pravastatin Sodium	16	suppressed
Enalapril Maleate	Enalapril Maleate	15	suppressed
Pradaxa	Dabigatran Etexilate Mesylate	15	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	15	14
Spiriva Respimat	Tiotropium Bromide	15	suppressed
Glipizide Er	Glipizide	14	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	14	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	14	suppressed
Benztropine Mesylate	Benztropine Mesylate	13	suppressed
Levetiracetam	Levetiracetam	13	suppressed
Midodrine Hcl	Midodrine Hcl	13	suppressed
Olanzapine	Olanzapine	13	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	13	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	13	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	12	suppressed
Chlorthalidone	Chlorthalidone	12	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	12	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	12	suppressed
Gemtesa	Vibegron	12	suppressed
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	12	suppressed
Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	12	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	12	suppressed
Prazosin Hcl	Prazosin Hcl	12	suppressed
Humalog	Insulin Lispro	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error